LFWD (46) CUPR (32) CLGN (50) MLSS (43) ⌘ Pro Terminal →

HeartSciences Inc. (HSCS) — RQD Stock Rating Cockpit

$3.61 +7.12% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

HeartSciences Inc. (HSCS) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $17.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HSCS)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

47.730 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE55% OF RANGE

L: $2$3.61H: $5

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 15 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on HSCS

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (35)

-35.0% ROIC with 59.1% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (40)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (47)

15/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like HSCS

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HSCS)

✓Walkthrough of HSCS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HSCS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +85.13%▲ ASCENDING CHANNEL

2026-10-30O $3.57H $3.61L $3.29C $3.61VOL 54.5K

RES: $5.95SUP: $2.20SMA50: $3.61SMA200: $2.72

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HSCS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HSCS Butterfly Map → + Track HSCS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -0.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HSCS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HSCS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HSCS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HSCS)

Health Care Rank #560 of 1016 ⚔️ LFWD vs HSCS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HSCS vs. LFWD, CUPR, CLGN, MLSS)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, HeartSciences Inc. (HSCS) ranks #560 by composite RQD confidence (43/100, grade D-) and #843 by equity capitalization ($17.5M). Within this direct 5-issuer industry benchmark cohort, MLSS leads on earnings valuation at 5.0x trailing P/E, while HSCS leads on capital efficiency and profitability with -35.0% ROIC and 59.1% gross margin. CLGN currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with HSCS at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HSCS ACTIVE HeartSciences Inc.	D-	43/100	—	59.1%	-35.0%	+7.12%	$17.5M	Benchmark Subject
LFWD Lifeward Ltd.	D	46/100	—	96.0%	-35.0%	+2.78%	$16.7M	/lfwd-vs-hscs →
CUPR Cuprina Holdings (Cayman) Limited (Class A)	E	32/100	—	-1.3%	-35.0%	-1.07%	$14.1M	/cupr-vs-hscs →
CLGN CollPlant Biotechnologies Ltd	D	50/100	—	64.8%	-35.0%	+11.39%	$12.7M	/clgn-vs-hscs →
MLSS Milestone Scientific Inc.	D-	43/100	5.0x	71.4%	-35.0%	-0.54%	$28.6M	/mlss-vs-hscs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-04-30 • CIK 0001468492

In its most recent audited fiscal period (FY2025, filed 2026-04-30), HeartSciences Inc. (HSCS) reported GAAP revenue of $4.3K (-0.7% vs. FY2024 revenue of $4.3K , and -76.8% cumulative change since FY2023) , GAAP net income of -$9.1M, operating cash flow of -$7.4M, and free cash flow of -$7.4M (-0.2% YoY). On the balance sheet, HSCS closed FY2025 with $4.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-04-30	$4.3K	-$9.1M	-$7.4M	-$7.4M	$4.2M	—
FY2024 (FY)	2025-04-30	$4.3K	-$8.8M	-$7.4M	-$7.4M	$5.7M	—
FY2023 (FY)	2024-04-30	$18.6K	-$6.6M	-$6.1M	-$6.1M	—	—

3. HSCS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HSCS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, HeartSciences Inc. (NASDAQ: HSCS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $3.61 (+7.12% 1D, market cap $17.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, HSCS ranks #560 in composite RQD confidence.

How does HSCS compare to LFWD and CUPR in the Health Care sector?

Within the Health Care sector (Industrial Specialties), HSCS carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of 59.1%, and ROIC of -35.0%. By comparison, LFWD (Lifeward Ltd.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $16.7M) and CUPR (Cuprina Holdings (Cayman) Limited (Class A)) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $14.1M). Among the 5-stock peer group, MLSS leads on earnings multiple (5.0x) while HSCS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HSCS?

Per HSCS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001468492), HeartSciences Inc. generated $4.3K in revenue (-0.7% YoY), -$9.1M in net income, and -$7.4M in free cash flow against $4.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HSCS trading relative to its 50-day, 200-day, and 52-week technical levels?

HSCS last traded at $3.61 (+7.12% on volume of 75,959 shares), positioning the stock 0.00% above its 50-day simple moving average ($3.61) and +32.72% above its 200-day simple moving average ($2.72). Across its 52-week range of $1.63 to $5.25, HSCS sits at the 54.7% percentile with a 14-day RSI of 47.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.16 to $4.06).

HSCS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell HSCS stock right now?

HeartSciences Inc. (HSCS) currently earns a Roarable Rating of D- (Sell — SELL) with 43/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is HSCS's 12-month price target and RQD AI Jury consensus?

HSCS's 12-month base price target is $3.37 (range $2.63 to $5.51), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: HSCS RQD Cockpit HSCS 12M Forecast HSCS Earnings & Move HSCS Dividends & DRIP HSCS Insiders & 13F HSCS Whale Options HSCS Profit Sankey HSCS News & Why